Evaxion Biotech A/S (EVAX)
Evaxion Biotech A/S Statistics
Share Statistics
Evaxion Biotech A/S has 315.83K shares outstanding. The number of shares has increased by 0.02% in one year.
| Shares Outstanding | 315.83K |
| Shares Change (YoY) | 0.02% |
| Shares Change (QoQ) | -0.48% |
| Owned by Institutions (%) | 15.81% |
| Shares Floating | 286.63K |
| Failed to Deliver (FTD) Shares | 257 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 102.32K, so 8.72% of the outstanding shares have been sold short.
| Short Interest | 102.32K |
| Short % of Shares Out | 8.72% |
| Short % of Float | 0.29% |
| Short Ratio (days to cover) | 1.07 |
Valuation Ratios
The PE ratio is -1.06 and the forward PE ratio is -1.56. Evaxion Biotech A/S's PEG ratio is 0.06.
| PE Ratio | -1.06 |
| Forward PE | -1.56 |
| PS Ratio | 320.92 |
| Forward PS | 0 |
| PB Ratio | -4.95 |
| P/FCF Ratio | -1.32 |
| PEG Ratio | 0.06 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Evaxion Biotech A/S.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.18, with a Debt / Equity ratio of -2.3.
| Current Ratio | 1.18 |
| Quick Ratio | 1.18 |
| Debt / Equity | -2.3 |
| Debt / EBITDA | -0.51 |
| Debt / FCF | -0.61 |
| Interest Coverage | -24.75 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.49K |
| Profits Per Employee | $-451.53K |
| Employee Count | 49 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -791.22K |
| Effective Tax Rate | 3.45% |
Stock Price Statistics
The stock price has increased by -91.6% in the last 52 weeks. The beta is -0.24, so Evaxion Biotech A/S's price volatility has been lower than the market average.
| Beta | -0.24 |
| 52-Week Price Change | -91.6% |
| 50-Day Moving Average | 2.37 |
| 200-Day Moving Average | 9.39 |
| Relative Strength Index (RSI) | 31.29 |
| Average Volume (20 Days) | 2.35M |
Income Statement
In the last 12 months, Evaxion Biotech A/S had revenue of 73K and earned -22.13M in profits. Earnings per share was -1.62.
| Revenue | 73K |
| Gross Profit | 72.89K |
| Operating Income | -22.2M |
| Net Income | -22.13M |
| EBITDA | -21.4M |
| EBIT | -22.02M |
| Earnings Per Share (EPS) | -1.62 |
Balance Sheet
The company has 5.58M in cash and 10.87M in debt, giving a net cash position of -5.29M.
| Cash & Cash Equivalents | 5.58M |
| Total Debt | 10.87M |
| Net Cash | -5.29M |
| Retained Earnings | -107.97M |
| Total Assets | 15.19M |
| Working Capital | 0 |
Cash Flow
In the last 12 months, operating cash flow was -17.69M and capital expenditures -87K, giving a free cash flow of -17.78M.
| Operating Cash Flow | -17.69M |
| Capital Expenditures | -87K |
| Free Cash Flow | -17.78M |
| FCF Per Share | -1.3 |
Margins
Gross margin is 99.85%, with operating and profit margins of -30406.85% and -30308.22%.
| Gross Margin | 99.85% |
| Operating Margin | -30406.85% |
| Pretax Margin | -31390.41% |
| Profit Margin | -30308.22% |
| EBITDA Margin | -29319.18% |
| EBIT Margin | -30406.85% |
| FCF Margin | -24353.42% |
Dividends & Yields
EVAX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for EVAX is $10, which is 545.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 545.2% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jan 14, 2025. It was a backward split with a ratio of 1:5.
| Last Split Date | Jan 14, 2025 |
| Split Type | backward |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | -12.43 |
| Piotroski F-Score | 3 |